Education
About Us
Working with TipRanks
Follow Us
BeOne Medicines (ONC)
NASDAQ:ONC
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$170.99 - $330.63
Previous CloseN/A
VolumeN/A
Average Volume (3M)403.59K
Market Cap
$37.63B
Enterprise Value$25.50B
Total Cash (Recent Filing)$2.76B
Total Debt (Recent Filing)$1.03B
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 06, 2025EPS Estimate
0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.91
Shares Outstanding109,600,310
10 Day Avg. Volume287,713
30 Day Avg. Volume403,593
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue5.59
Enterprise Value/Gross Profit6.54
Enterprise Value/Ebitda285.72
Forecast
1Y Price Target
$356.83Price Target Upside19.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Financial PerformanceONC reported total product revenues of ~$1.3bn, representing a ~17% QoQ increase.
Market PositionBrukinsa is highlighted as the market share/value share leader, the fastest growing brand, and the only BTK approved in five indications.
Product DevelopmentBGB-43395 (CDK4 inhibitor) has shown a favourable hematologic safety profile in combination with fulvestrant, indicating potential future success in clinical trials.
Bears Say
Clinical DataIt is too early to assess the efficacy of BeOne’s CDK4 inhibitor due to limited follow-up, making current response data inconclusive.
Product EfficacyPromising safety/tolerability shown for BGB-43395 (CDK4i), although efficacy numerically lower than PFE's (MP, Risinger) atirmociclib.
BeOne Medicines News
ONC FAQ
What was BeOne Medicines’s price range in the past 12 months?
BeOne Medicines lowest stock price was $170.99 and its highest was $330.63 in the past 12 months.
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $37.63B.
When is BeOne Medicines’s upcoming earnings report date?
BeOne Medicines’s upcoming earnings report date is Nov 06, 2025 which is in 68 days.
How were BeOne Medicines’s earnings last quarter?
BeOne Medicines released its earnings results on Aug 06, 2025. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.387 by $0.523.
Is BeOne Medicines overvalued?
According to Wall Street analysts BeOne Medicines’s price is currently Undervalued.
Does BeOne Medicines pay dividends?
BeOne Medicines does not currently pay dividends.
What is BeOne Medicines’s EPS estimate?
BeOne Medicines’s EPS estimate is 0.7.
How many shares outstanding does BeOne Medicines have?
BeOne Medicines has 109,600,310 shares outstanding.
What happened to BeOne Medicines’s price movement after its last earnings report?
BeOne Medicines reported an EPS of $0.91 in its last earnings report, beating expectations of $0.387. Following the earnings report the stock price went down -2.835%.
Which hedge fund is a major shareholder of BeOne Medicines?
Currently, no hedge funds are holding shares in ONC
BeOne Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$356.83 (19.76% Upside)
$356.83 (19.76% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 115.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.3%
Last 30 Days ▼ 10.5%
Last 30 Days ▼ 10.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.45%
12-Months-Change
Fundamentals
Return on Equity
-4.95%
Trailing 12-Months
Asset Growth
10.26%
Trailing 12-Months
Company Description
BeOne Medicines
BeOne Medicines (ONC) is a biotechnology company focused on developing innovative therapeutic solutions for cancer and other serious diseases. The company operates primarily in the biopharmaceutical sector, leveraging advanced technologies to create targeted treatments that aim to improve patient outcomes. BeOne Medicines is recognized for its proprietary drug development platforms and its commitment to precision medicine, offering a range of products designed to address unmet medical needs in oncology and beyond.
ONC Company Deck
ONC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and market leadership, particularly with BRUKINSA's success. Significant progress was noted in pipeline developments and global market expansion. Despite facing competition and challenges in fixed duration therapies, the company's achievements and optimistic outlook for future milestones contributed to a broadly positive sentiment.View all ONC earnings summariesONC Stock 12 Month Forecast
Average Price Target
$356.83
▲(19.76% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---